However, CD19+ and CD4+ were not significantly associated with patient outcomes in the multivariate analysis including age, pathological type, tumor size, ER status, PR status, HER2 status, Ki67 status, visceral invasion, multiple invasion, menstrual status, and treatment conditions (data not shown). This evidence concerns the gene ERBB2 and neoplasm.